AI and Life Science Patents: Strategies for Patenting AI-Driven Innovations and Predicting the Impact of the New EU Artificial Intelligence Act on Patent Strategies in Europe
Eileen Brandenburger
Head of IP | Patent Attorney
Exscientia
David Sanker
Partner
Morgan, Lewis & Bockius LLP
- Assessing the latest ways that AI is being used in drug development
- Analyzing how patent registries and courts are interpreting the existing law in Europe and the U.S. regarding patenting and protecting AI-driven innovations
- Understanding how companies are navigating patenting challenges surrounding:
- Eligibility disputes surrounding unpatentable subject matter
- Satisfaction of the written description and enablement requirements
- Issues of inventorship and conception
- Examining the EU Artificial Intelligence Act which is expected to come into force near the end of 2023
- What will the implications be on AI patenting?
- How will provisions of the new Act potentially open up a growing area of infringement litigation in the life sciences space?